Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Pacific Biosciences of California, Inc. PACB

Set alert

Price alert · PACB

All alert types
2.35 USD -0.26 -9.98%

At close

2.40 +0.05 +2.35%

Pre-market · Nov 3, 8:31 AM ET

Bid
2.34 × 2
Ask
2.35 × 1
2.31 Day range 2.72
1.07 52-week range 3.44
YTD
+25.40%
1 year
+4.69%
Open
2.68
Prev close
2.61
Mkt cap
728.90M
Vol
9.10M
Avg vol
12.11M
EPS
-0.43
P/E
0.00
Div yield
0.00%
More statistics
Low
2.31
High
2.72
Forward P/E
-2.84
Beta
2.01
Short ratio
4.46
Inst. own
84.53%
Dividend
0.00
Ex-div date
50-d avg
2.01
200-d avg
2.02
1y target
3.02

6M chart

Chart tools
Interval
1m5m15m30m

Signals (28)
NameDateAgo
MACD: Buy SignalOct 28, 20266 days ago
RSI: OverboughtOct 28, 20266 days ago
MACD: Sell SignalOct 13, 20263 weeks ago
RSI: OverboughtSep 28, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BullishSep 17, 20261 month ago
MACD: Buy SignalSep 15, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BearishAug 28, 20262 months ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BullishAug 25, 20262 months ago
MACD: Buy SignalAug 20, 20262 months ago
SMA: BearishJul 31, 20263 months ago
SMA: BearishJul 31, 20263 months ago
SMA: BullishJul 30, 20263 months ago
SMA: BullishJul 30, 20263 months ago
SMA: BearishJul 17, 20263 months ago
MACD: Sell SignalJul 10, 20263 months ago
SMA: BullishJun 25, 20264 months ago

Newest 20 of 28.

Analyst view

Consensus: buy

Buy
Price target (mean) 3.02 +28.8% upside
Target (low)
2.00
Target (mean)
3.02
Target (high)
6.00
Ratings (0m) 15 7 buy · 8 hold · 0 sell
  • Strong buy1
  • Buy6
  • Hold8
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 15
  • 1 month ago 15
  • 2 months ago 14
  • 3 months ago 14

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PACB analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.17551-0.21 – -0.11-0.27+35.0%40.66M-30.3%11
Next quarter-0.15903-0.19227 – -0.13-0.26+38.8%42.54M+9.6%8
Current year-0.81244-0.89123 – -0.74-1.11+26.8%155.49M-22.5%12
Next year-0.63882-0.74484 – -0.54-0.81244+21.4%191.23M+23.0%12

Upgrades and downgrades

The latest rating changes

PACB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2024UBSDowngradeBuyNeutral
Nov 11, 2024ScotiabankMaintainedSector OutperformSector Outperform
Nov 11, 2024Piper SandlerMaintainedNeutralNeutral
Aug 28, 2024ScotiabankMaintainedSector OutperformSector Outperform
Aug 13, 2024Stephens & Co.MaintainedOverweightOverweight
Aug 12, 2024Morgan StanleyMaintainedEqual-WeightEqual-Weight
Aug 8, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Aug 8, 2024Canaccord GenuityMaintainedBuyBuy
Jun 3, 2024JefferiesInitiated—Buy
May 15, 2024Morgan StanleyMaintainedEqual-WeightEqual-Weight
May 13, 2024Piper SandlerMaintainedNeutralNeutral
May 10, 2024BarclaysMaintainedEqual-WeightEqual-Weight
Apr 22, 2024JP MorganDowngradeOverweightNeutral
Apr 19, 2024Goldman SachsMaintainedNeutralNeutral
Apr 18, 2024BernsteinMaintainedOutperformOutperform
Apr 18, 2024Goldman SachsDowngradeBuyNeutral
Apr 18, 2024ScotiabankMaintainedSector OutperformSector Outperform
Apr 17, 2024TD CowenMaintainedBuyBuy
Apr 10, 2024BarclaysMaintainedEqual-WeightEqual-Weight
Apr 10, 2024Goldman SachsMaintainedBuyBuy
Mar 22, 2024Canaccord GenuityMaintainedBuyBuy
Feb 16, 2024UBSMaintainedBuyBuy
Dec 14, 2023GuggenheimInitiated—Neutral
Dec 14, 2023Stephens & Co.Initiated—Overweight
Dec 13, 2023Wolfe ResearchInitiated—Peer Perform
Nov 17, 2023UBSUpgradeNeutralBuy
Nov 6, 2023Piper SandlerMaintainedNeutralNeutral
Oct 31, 2023Canaccord GenuityMaintainedBuyBuy
Oct 31, 2023Cantor FitzgeraldUpgradeNeutralOverweight
Oct 24, 2023Morgan StanleyMaintainedEqual-WeightEqual-Weight